MLTX
MoonLake Immunotherapeutics
10.60$
-1.8%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 0.0% | +9,872.6% | +4.3% | +2.6% | +270.7% | -71.0% | +96.3% | +0.4% | +0.8% | +12.5% | +6.0% | – | |
| – | +12.6% | +4.5% | +9.0% | +0.8% | +4.9% | +18.4% | +44.5% | +12.1% | -3.2% | +272.0% | -80.9% | – | |
| – | -746.8% | – | – | – | -147.1% | – | – | – | -101.7% | – | – | – | |
| – | – | -25.5% | -100.0% | +4,399,900.0% | +33.0% | -80.1% | -100.0% | – | – | – | – | – | |
| – | – | -124.6% | +204.6% | – | -352.8% | – | +56.9% | +0.2% | -133.8% | – | +228.6% | – | |
| – | – | – | -100.0% | – | -100.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -100.0% | – | – | – | -100.0% | – | |
| – | – | +79.4% | -100.0% | – | -17.6% | +48,419.6% | -100.0% | – | +14,982.3% | -57.7% | +665.6% | – | |
| – | – | -94.5% | -1,690.3% | – | -694.1% | – | -61.5% | +25.5% | -136.8% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.